Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 in Ulin Regional Hospital Banjarmasin

Haryati*, Mohamad Isa, Ali Assagaf, Ira Nurrasyidah, Erna Kusumawardhani
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin Regional Hospital, Banjarmasin, Indonesia.

Background: Corona Virus Disease (COVID-19) has become a global pandemic and has spread to more than 200 countries including Indonesia. South Kalimantan is one of the provinces in Indonesia that has a high COVID-19 mortality rate (case fatality rate 4.1%). Information about characteristic of mortality patients with SARS-CoV-2 infection in Indonesia was limited. The objective of this study to describe clinical characteristics of COVID-19Confirmed deaths at Ulin Regional Hospital Banjarmasin, as a referral hospital in South Kalimantan.

Methods: Medical records of 108 hospitalized patients dying with COVID-19 between March until August 2020 were collected. The recorded information included gender, age, onset and severity of disease, comorbidities, symptoms, signs, and laboratory findings.

Results: The 108 confirmed cases of COVID-19 deaths were mostly male (73.1%) aged <65 years old (85.2%). About 84% of the cases had at least one comorbidity or more, like hypertension (44.4%), obesity (38%), and diabetes mellitus (32.4%). Common early symptoms were fever (91.7%) and shortness of breath (89.8%). Laboratory findings included lymphocytopenia and eosinopenia (80.6% and 72.2%), increased neutrophil lymphocyte ratio (NLR; 86.1%), decreased absolute lymphocyte count (ALC; 72.2%), and hyponatremia (55.6%). Elevated C-reactive protein (CRP; 92.6%), lactate dehydrogenase (LDH; 91.7%), serum glutamic oxaloacetic transaminases (SGOT; 82.4%), and creatinine levels (57.4%). The majority of non-survivors were severe- Critical stage with severe acute respiratory distress syndrome (ARDS).

Conclusion: In this descriptive study, patients with comorbidities and severe-critical stage are at risk of death. Laboratory abnormalities were common in non-survivors. Shortness of breath may indicate poor prognosis of COVID-19.

INTRODUCTION

World Health Organization (WHO) has determined that Corona Virus Disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 has become a global pandemic.1,2 Currently, COVID-19 has spread to more than 200 countries including Indonesia.3 Clinical manifestations of COVID-19 patients have a broad spectrum, ranging from symptomless (asymptomatic), mild symptoms, pneumonia, severe pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, sepsis, to shock.

*Correspondence: haryatiharsono@yahoo.com

This work is licensed under a Creative Commons Attribution-Share Alike 4.0 International License.
mortality rate occurs in elderly and is dominated by male.⁷

South Kalimantan is one of the provinces in Indonesia that has a high COVID-19 mortality rate (CFR 4.1%).⁸ Some studies abroad mention that age and comorbidity (hypertension, diabetes, heart disease, and so forth) are the most important risk factors associated with death from COVID-19.⁹,¹⁰ The most common organ damage caused by COVID-19 is the lungs, followed by the heart, kidneys, liver, and hematology.⁷,⁹,¹¹,¹² Patients who died at the age of ≥65 years old had a higher number of comorbidities than the age of <65 years old. However, non-respiratory complications such as acute renal failure, cardiac injury, and superinfection are actually higher in young adult patients.¹⁰ Some laboratory variables such as lymphocytes, neutrophils, platelets, amyloid serum A (SAA), procalcitonin (PCT), cardiac thromboxine I (cTnI), D-dimer, lactate dehydrogenase (LDH), and lactate serum can be used as indicators of disease progressiveness.⁹,¹¹ Some of these clinical phenomena illustrate that pathogenesis of COVID-19 disease is highly complex. Meanwhile, in Indonesia, research about the characteristics of COVID-19 patients who died is still limited.

From March to August 2020 Ulin Regional Hospital Banjarmasin as a COVID-19 referral hospital in South Kalimantan has treated a number of COVID-19 patients. In this study, 108 patients were analyzed to describe the characteristics of COVID-19 confirmed patients at Ulin Regional Hospital Banjarmasin from March to August 2020 with the aim of identifying an overview of risk factors associated with mortality in COVID-19 patients. It is hoped that the results of this study can assist in the stratification of the risk of patients with SARS-CoV2 infection, thus further intervention can be given on time to avoid disease progression, as well as to improve the outcome of the patients infected with COVID-19 and reduce the mortality rate from COVID-19 in the future.

METHODS

This research was a retrospective study using epidemiological, clinical, and laboratories data extracted from the medical records of COVID-19 confirmed patients who died at Ulin Regional Hospital Banjarmasin in the period of March until August 2020. A confirmed diagnosis of COVID-19 is defined as someone who is declared positively infected with COVID-19 virus as evidenced by laboratory examination of reverse transcriptase-polymerase chain reaction (RT-PCR). This research had been approved by the Research Ethics Committee of Ulin Regional Hospital Banjarmasin.

The sample selection technique in this study used total sampling and obtained the number of research subjects as many as 108 patients. The inclusion criteria in this study were the medical records of all COVID-19 confirmed patients who died in the period of March until August 2020, and the exclusion criteria were incomplete medical records of patients according to the specified variables. The variables examined in this study were the initial data of patients upon hospital admission consisting of epidemiological data namely gender, age, onset of disease (from the beginning of complaints to hospital admission, and from the beginning of rising complaints until the patient dies), and the severity of the disease at the beginning of hospital admission (asymptomatic, mild degree, moderate [pneumonia (+), SaO2 ≥ 93% room air], severe [SaO2 < 93% room air], critical [ARDS, PaO2/FiO2 < 300 mmHg]) and comorbidities. Clinical descriptions of COVID-19 patients were clinical symptoms and laboratory analysis including complete blood count (haemoglobin (Hb), leukocytes, platelets, neutrophil count, eosinophils, and lymphocyte count), liver function, renal function, electrolyte serum, C-reactive protein (CRP), LDH, and other viral infection status (neutrophil lymphocyte ratio [NLR] and absolute lymphocyte count [ALC]). The onset date of the disease, the initial date of hospital admission, the initial diagnosis of COVID-19, and death were accurately recorded. The data was then collected using a computer program according to a standard form that had been designed before and then tabulated. The results were displayed in the form of a table.

RESULTS

Based on 108 confirmed cases of COVID-19 who died at Ulin Regional Hospital Banjarmasin in the period of March until August 2020, it obtained clinical characteristics data presented in Table 1.
| Variables                  | Frequency | Percentage (%) |
|----------------------------|-----------|----------------|
| **Gender**                 |           |                |
| Men                        | 79        | 73.1%          |
| Women                      | 29        | 26.9%          |
| **Age Group**              |           |                |
| ≥65 years old              | 16        | 14.8%          |
| <65 years old              | 38        | 85.2%          |
| 55-64 years old            | 30        | 35.2%          |
| 45-54 years old            | 18        | 27.8%          |
| 35-44 years old            | 6         | 16.7%          |
| 25-34 years old            | 0         | 5.6%           |
| 18-24 years old            | 16        | 0.0%           |
| **Onset Disease until**    |           |                |
| Hospital Admission         |           |                |
| <7 days                    | 57        | 52.8%          |
| 7-14 days                  | 44        | 40.7%          |
| 15-21 days                 | 2         | 1.9%           |
| >21 days                   | 4         | 3.7%           |
| **Onset Disease until**    |           |                |
| Patient's Death            |           |                |
| <7 days                    | 13        | 12.0%          |
| 7-14 days                  | 49        | 45.4%          |
| 15-21 days                 | 25        | 23.1%          |
| >21 days                   | 20        | 18.5%          |
| **Degree of Disease Severity** |       |                |
| Asimptomatic               | 0         | 0.0%           |
| Mild                       | 0         | 0.0%           |
| Moderate                   | 3         | 2.8%           |
| Severe                     | 10        | 9.3%           |
| Critical                   | 95        | 88.0%          |
| Mild ARDS                  | 19        | 17.6%          |
| Moderate ARDS              | 31        | 28.7%          |
| Severe ARDS                | 45        | 41.7%          |
| **Comorbidty**             |           |                |
| Hypertension               | 48        | 44.4%          |
| Diabetes Mellitus          | 35        | 32.4%          |
| Cardiovascular Disease     | 22        | 20.4%          |
| Cerebrovascular Disease    | 3         | 2.8%           |
| Chronic Kidney Disease     | 13        | 12.0%          |
| Chronic Lung Disease       | 11        | 10.2%          |
| Chronic Liver Disease      | 4         | 3.7%           |
| Malignancy                 | 4         | 3.7%           |
| Obesity                    | 41        | 38.0%          |
| **Number of Comorbidities**|           |                |
| 0                          | 16        | 14.8%          |
| 1                          | 35        | 32.4%          |
| 2                          | 33        | 30.6%          |
| ≥3                         | 24        | 22.2%          |
| **Early Symptom**          |           |                |
| Fever/Fever History        | 99        | 91.7%          |
| Shortness of Breath        | 97        | 89.8%          |
| Cough                      | 82        | 75.9%          |
| Sore Throat                | 17        | 15.7%          |
| Colds                      | 4         | 3.7%           |
| Haemoptysis                | 2         | 1.9%           |
| Anosmia                    | 2         | 1.9%           |
| Nausea/Vomiting            | 39        | 36.1%          |
| Diarrhea                   | 16        | 14.8%          |
| Myalgia/ Artralgia         | 1         | 0.9%           |
| Fatigue                    | 29        | 26.9%          |
| Headaches                  | 3         | 2.8%           |
| Subflebris                 | 16        | 14.8%          |

| Laboratory                  |             |               |
|-----------------------------|-------------|---------------|
| **Haemoglobin**             |             |               |
| >18.0 g/dl                  | 0           | 0.0%          |
| 12.0 – 18.0 g/dl            | 84          | 77.8%         |
| <12.0 g/dl                  | 24          | 22.2%         |
| **Leukocyte**               |             |               |
| >10.5 x 10E3/ul             | 47          | 43.5%         |
| 4.0 – 10.5 x 10E3/ul        | 55          | 50.9%         |
| <4.0 x 10E3/ul              | 6           | 5.6%          |
| **Platelets**               |             |               |
| >450 x 10E3/ul              | 12          | 11.1%         |
| 150 – 450 x 10E3/ul         | 82          | 75.9%         |
| <150 x 10E3/ul              | 14          | 13.0%         |
| **Neutrophils**             |             |               |
| <50%                        | 2           | 1.9%          |
| 50 – 81%                    | 54          | 50.0%         |
| >81%                        | 52          | 48.1%         |
| **Lymphocyte**              |             |               |
| <20%                        | 87          | 80.6%         |
| 20 – 40%                    | 18          | 16.7%         |
| >40%                        | 3           | 2.8%          |
| **Eosinophil**              |             |               |
| <1%                         | 78          | 72.2%         |
| 1-3%                        | 28          | 25.9%         |
| >3%                         | 2           | 1.9%          |
| **NLR**                     |             |               |
| <3.13                       | 15          | 13.9%         |
| ≥3.13                       | 93          | 86.1%         |
| **ALC**                     |             |               |
| >1500                       | 30          | 27.8%         |
| ≤1500                       | 78          | 72.2%         |
| **Liver Function**          |             |               |
| SGOT                        | 5 – 34 U/L  | 19            |
| >34 U/L                     | 89          | 82.4%         |
| **SGPT**                    |             |               |
| 0 – 55 U/L                  | 66          | 61.1%         |
| >55 U/L                     | 42          | 38.9%         |
| **Renal Function**          |             |               |
| Ureum                       |             |               |
| 0 – 50 mg/dl                | 58          | 53.7%         |
| >50 mg/dl                   | 50          | 46.3%         |
| **Creatinin**               |             |               |
| <1.25 mg/dl                 | 46          | 42.6%         |
| ≥1.25 mg/dl                 | 62          | 57.4%         |
| **CRP**                     |             |               |
| < 6.00 mg/dl                | 8           | 7.4%          |
| ≥6.00 mg/dl                 | 100         | 92.6%         |
| **LDH**                     |             |               |
| <122                        | 5           | 4.6%          |
| 122 – 220 U/L               | 4           | 3.7%          |
| >220 U/L                    | 99          | 91.7%         |
| **Natrium**                 |             |               |
| >145 Meq/L                  | 4           | 3.7%          |
| 136-145 Meq/L               | 44          | 40.7%         |
| <136 Meq/L                  | 60          | 55.6%         |
| **Potassium**               |             |               |
| >5.1 Meq/L                  | 9           | 8.3%          |
| 3.5-5.1 Meq/L               | 84          | 77.8%         |
| <3.5 Meq/L                  | 15          | 13.9%         |
| **Chlorida**                |             |               |
| >107 Meq/L                  | 40          | 37.0%         |
| 98-107 Meq/L                | 55          | 50.9%         |
| <98 Meq/L                   | 13          | 12.0%         |
Data on the table showed 73.1% of the cases were male and 85.2% of the cases aged <65 years old with the most age range being 55-64 years old (35.2%). A total of 52.8% of the cases experienced COVID-19 symptoms ≤7 days before being hospitalized at Ulin Regional Hospital Banjarmasin. Most patients had the number of days from onset to death in the range of 7-14 days (45.4%). The majority of the cases had critical degree of severity (88%) and 41.7% of the cases had severe ARDS. About 84% of the cases had comorbidity of at least one or more. The most common comorbidities were hypertension (44.4%), obesity (38%), and diabetes mellitus (32.4%). The most common early clinical symptoms were fever (91.7%), shortness of breath (89.8%), and cough (75.9%).

Laboratory results showed the majority of the cases had haemoglobin, leukocyte, platelet, and neutrophil values within the normal range, while lymphocytes and eosinophils tended to decrease by <20% and <1% (80.6% and 72.2%), Elevated CRP (≥6.00 mg/dl) in 92.6% of the cases and LDH (>220 U/L) in 91.7% of the cases. There were an increase in NLR results (≥3.13) in 86.1% of the cases and a decreased ALC (<1500) in 72.2% of the cases. Liver function tests showed an increase in serum glutamic oxaloacetic transaminases (SGOT) in 82.4% of the cases, while serum glutamic pyruvic transaminases (SGPT) at 61.1% of the cases was within normal limits. Renal function tests showed normal urea levels in 53.7% of the cases, but there was an increase in creatinine levels (>1.25 mg/dl) in 57.4% of the cases. Electrolyte test results showed the absence of hyponatremia (<136 Meq/L) in 55.6% of the cases, while potassium and chloride levels of most patients were within normal limits.

**DISCUSSION**

A number of cases of COVID-19 deaths at Ulin Hospital Banjarmasin are dominated by male, aged <65 years old with one or more comorbidities and severity of critical illness (ARDS). The number of deaths in men is greater than women at 2.7:1. This study is comparable to some studies which also mention that mortality in men is higher than in women. It is estimated due to the association of male with the prevalence of active smokers, the absence of comorbidity (hypertension and diabetes mellitus) resulting in increased expression of angiotensin converting enzyme (ACE)-2 receptors is higher in men than in women. In addition, women are thought to be able to fight the virus better due to the protection of the X chromosome and sex hormone (estrogen) which plays an important role in innate and adaptive immunity.

Age and comorbidity are the most influential risk factors in COVID-19 mortality. Some studies show that the age group that has high mortality in COVID-19 is ≥65 years old. This is associated with several things including decreased physiological immunity and the absence of comorbidities that contribute to a decrease in the body's functional reserves, thus reducing the capacity and the ability to fight infections. Nevertheless, in this study, the most mortality occurred at <65 years old (55-64 years old) with most cases having only one comorbidity (32.4%). This is expected because the distribution of COVID-19 patients treated at Ulin Hospital Banjarmasin is dominated by patients <65 years old. It was mentioned that COVID-19 patients with young adulthood have less comorbidity than the elderly. However, they are more likely to die with complications that develop during treatment. In addition to the onset of symptoms up to hospital admission in patients <65 years old longer than the elderly, this suggests that delayed hospital referrals lead to less optimal care and increase the risk of disease progression and complications.

Certain comorbidities are associated with strong ACE-2 receptor expression and higher release of proprotein convertase which increases the entry of the virus into the host cell. Comorbidity causes COVID-19 patients to be substantially associated with morbidity and significant mortality. The most common comorbidities found in COVID-19 cases are hypertension, diabetes mellitus, and cardiovascular disease, in which all three diseases are associated with high mortality rates in COVID-19 patients. In this study, obesity was ranked as the 3rd most common comorbidity in addition to hypertension and diabetes mellitus. It had been previously known that the age group with the highest mortality rate in this study was <65 years old (85.2%). According to the research by Steinberg E., et al., it mentioned that obesity is an...
was also a sharp decrease in his research stated that the incidence of lymphopenia is strongly related to intensive care (ICU) and death. In general, the incubation period of COVID-19 is 3-14 days (median 5 days) with frequent symptoms being fever, cough, and fatigue. In this study, the initial symptoms of COVID-19 patients who died were fever/history of fever, cough, and shortness of breath with the majority of patients (54.4%) had experienced these symptoms within <7 days before finally being hospitalized. According to its pathophysiology, symptoms of shortness of breath in COVID-19 generally appear in the second attack which is about 4-7 days after the virus spreads through the bloodstream to the tissue expressing ACE-2 such as the lungs, heart, and gastrointestinal tract. Shortness of breath can also be a marker that pulmonary function has begun to be impaired until pneumonia and ARDS emerge. In addition, the absence of symptoms of shortness of breath is also associated with a poor prognosis.

Viral infections can cause inflammation of the human body. Various inflammatory mediators produced during cytokine storms can cause systemic immune damage and even multi-organ failure. In this study, haemoglobin, platelets, leukocytes, and neutrophils in early screening of COVID-19 patients tended to be normal with increased NLR and decreased lymphocytes, eosinophils, and ALC. The results of this study are comparable to several other studies showing that the characteristics of haemoglobin levels in COVID-19 patients tend to be normal, with normal or decreased platelet and leukocyte values (lymphopenia) accompanied by an increase in NLR and a decrease in ALC. A large number of clinical studies have reported the incidence of lymphopenia in COVID-19 patients which can be considered a meaningful sign for COVID-19 infection, where patients with pneumonia have lower lymphocytes compared to patients without pneumonia. In addition, there was also a sharp decrease in ALC, especially in cases of severe and critical degrees. Another interesting finding related to COVID-19 infections reported by some studies is eosinopenia, as in the results of this study. Recent findings suggest that eosinophils have important antiviral properties where granular proteins derived from eosinophils (eosinophil-derived neutrotoxins and eosinophil cationic proteins) exhibit antiviral activity against single-chain ribonucleic acid (RNA) viruses. In addition, eosinophils are capable of producing nitric oxide and can induce the proliferation and activation of CD8+ T cells in response to exposure to viruses. The research of Zhang J. J., et al. of 140 hospitalized patients suggests that eosinopenia with lymphopenia can be a potential indicator for COVID-19 as a diagnostic and prognostic value. Du, et al. also reported that eosinopenia can be indicated as poor prognostic value in COVID-19 patients. On the other hand, this study also found as much as 43.5% of the cases of increased number of leukocytes that are suspected of other infections including bacterial infections. Zheng Z., et al. in his research stated that the increase in the number of leukocytes at the beginning of COVID-19 patient screening may be related to the absence of other infections and may worsen the prognosis of COVID-19.

In this study, there was an increase in the levels of SGOT, creatinine, LDH, and CRP similar to some other studies. Increased levels of SGOT and creatinine indicate the presence of renal and liver dysfunction. This phenomenon can occur in part because of the direct effects of SARS CoV-2 infection that causes cytokine storms. Aside from lungs and blood vessels, ACE-2 expression is also obtained in the kidneys, heart, liver, and other organs, thus SARS-CoV-2 can attack and damage those organs which then gives rise to immune cells to produce pro-inflammatory cytokines, cytokine storms that ultimately lead to tissue injury and failure of target organs. Bloom, et al. in his study mentioned that COVID-19 patients with increased SGOT require more intubation action. In addition, increased SGOT was also associated with hepatitis and myositis/heart damage infections. Research conducted by Cheng, et al. showed that patients who experienced an increase in serum creatinine at the beginning of hospitalization had a greater likelihood of being treated in an intensive care unit (ICU) and required mechanical ventilation, thus it can be said that kidney abnormalities at the beginning of hospitalization represent a higher risk of worsening.

In addition to kidney and liver damage, the increase in LDH and CRP in COVID-19 patients also
represents an overview of lung damage and respiratory distress due to inflammatory processes, thus it can be used to predict respiratory failure (ARDS). The increase in CRP is said to have a correlation with an increase in the area of pulmonary lesions, while an increase in LDH may indicate an increase in inflammatory processes and lung damage rates incriminated ill COVID-19 patients. A study showed significantly higher LDH levels in ICU patients compared to non-ICU patients.

Some studies have shown that the majority of COVID-19 cases have electrolyte abnormalities correlated with a high risk of intensive care needs, mechanical ventilation and encephalopathy events with high mortality rates and longer treatment days. Comparable to some other studies, most cases found that most cases had hyponatremia (55.6%). Tezcan, et al. mentions that hyponatremia is the most common electrolyte abnormality compared to other electrolyte abnormalities. In addition, hyponatremia can also be used as an independent predictor of poor prognosis in COVID-19 patients.

One of the clinical picture in COVID-19 is the development of lung injuries that have the potential to cause ARDS. Pneumonia and ARDS usually develop in the course of infection between 5-10 days from the onset of clinical symptoms. ARDS is one of the leading causes of death in COVID-19 patients. The cause of ARDS in COVID-19 cases is cytokine storms, which are uncontrolled systemic inflammatory responses due to the release of large amounts of proinflammatory cytokines. In this study, 88% of COVID-19 patients who died were in critical condition and were dominated by severe ARDS conditions.

In this study, the sample used was quite a lot with complete data but had limitations because it did not exclude some cases of COVID-19 that had previously undergone treatment in other health facilities, thus there was a possibility of treatment of patients that could affect the results of the initial examination when the patient was hospitalized at Ulin Regional Hospital Banjarmasin.

CONCLUSION

COVID-19 deaths at Ulin Regional Hospital Banjarmasin from March to August 2020 were dominated by severe-critical degree cases consisting mostly of male, aged <65 years old with one or more comorbidities. Hypertension, diabetes mellitus, and obesity were the most commonly found comorbidities with early symptoms of fever, cough, and shortness of breath. Laboratory results in most cases showed haemoglobin, platelets, leukocytes, and neutrophils tended to be normal with increased NLR, as well as decreased lymphocytes, eosinophils, and ALC. Natrium levels tended to decrease and there was an increase in SGOT, creatinine, CRP, and LDH.

REFERENCES

1. Organization WH. Coronavirus Update. Geneva, https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjO0mt9BhChRIsAKYDH7sv2HW-9qXR BPM30U0mjKrCzwqDOL59CvLaTidAF8ABi8A R2a-CBeEaAjqEALw_wcB (2020).
2. Indonesia KKR. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Jakarta, https://covid19.go.id/p/protocol/pedoman-pencegahan-dan-pengendalian-coronavirus-disease-covid-19 (2020).
3. Nasional KPC-19 dan PE. Indonesia’s Task Force for COVID-19. Jakarta, 2020.
4. Fu L, Wang B, Yuan T, et al. Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in China: A Systematic Review and Meta-Analysis. J Infect 2020; 80: 656–665.
5. Nagpal P, Narayanasamy S, Vidholia A, et al. Imaging of COVID-19 Pneumonia: Patterns, Pathogenesis, and Advances. Br J Radiol 2020; 93: 20200538.
6. Indonesia KKR. Indonesia’s Emerging Infection for COVID-19. Jakarta, https://infeksiemerging.kemkes.go.id/ (2020).
7. Karyono D, Wicaksana A. Current Prevalence, Characteristics, and Comorbidities of Patients with COVID-19 in Indonesia. J Community Empower Heal 2020; 3: 82–89.
8. Selatan DKPK. Informasi Terbaru COVID-19 di Kalimantan Selatan. Banjarmasin, http://dinkes.kalselprov.go.id/berita/informasi-terbaru-covid-19-di-kalimantan-selatan-8-november-2020.html (2020).
9. Li X, Wang L, Yan S, et al. Clinical Characteristics of 25 Death Cases with COVID-19: A Retrospective Review of Medical Records in a Single Medical Center, Wuhan, China. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2020; 94: 128–132.
10. Palmieri L, Vanacore N, Donfrancesco C, et al. Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 by Age Group in Italy. J Gerontol A Biol Sci Med Sci 2020; 75: 1796–1800.
11. Zhang B, Zhou X, Qiu Y, et al. Clinical Characteristics of 82 Cases of Death from COVID-19. PLoS One 2020; 15: e0235458.
12. Xie J, Tong Z, Guan X, et al. Clinical Characteristics of
Patients Who Died of Coronavirus Disease 2019 in China. *JAMA Netw Open* 2020; 3: e205619.

13. Jin J-M, Bai P, He W, et al. Gender Differences in Patients with COVID-19: Focus on Severity and Mortality. *Front Public Health* 2020; 8: 152.

14. Susilo A, Rumende C, Pitoyo C, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indonesia* 2020; 7: 45.

15. Zheng Z, Peng F, Xu B, et al. Risk Factors of Critical & Mortal COVID-19 Cases: A Systematic Literature Review and Meta-Analysis. *J Infect* 2020; 81: e16–e25.

16. Wortham JM, Lee JT, Althomsons S, et al. Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69: 923–929.

17. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality among COVID-19 Patients: A Meta-Analysis. *J Community Health* 2020; 45: 1270–1282.

18. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and Comorbidities: Deleterious Impact on Infected Patients. *J Infect Public Health* 2020; 13: 1833–1839.

19. Steinberg E, Wright E, Kushner B. In Young Adults with COVID-19, Obesity is Associated with Adverse Outcomes. *West J Emerg Med* 2020; 21: 752–755.

20. Hajifathalian K, Kumar S, Newberry C, et al. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. *Obesity (Silver Spring)* 2020; 28: 1606–1612.

21. Allali G, Marti C, Grosgrurin O, et al. Dyspnea: The Vanished Warning Symptom of COVID-19 Pneumonia. *J Med Virol* 2020; 92: 2272–2273.

22. Xie J, Covassin N, Fan Z, et al. Association between Hypoxemia and Mortality in Patients with COVID-19. *Mayo Clin Proc* 2020; 95: 1138–1147.

23. Fan BE, Chong VCL, Chan SSW, et al. Hematologic Parameters in Patients with COVID-19 Infection. *American Journal of Hematology* 2020; 95: E131–E134.

24. Usul E, Şan İ, Bekgöz B, et al. Role of Hematological Parameters in COVID-19 Patients in the Emergency Room. *Biomark Med* 2020; 14: 1207–1215.

25. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; 382: 1708–1720.

26. Jesenak M, Brndiarova M, Urbancikova I, et al. Immune Parameters and COVID-19 Infection - Associations with Clinical Severity and Disease Prognosis. *Front Cell Infect Microbiol* 2020; 10: 364.

27. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver Biochemistries in Hospitalized Patients with COVID-19. *Hepatology*. Epub ahead of print May 2020. DOI: 10.1002/hep.31326.

28. Cheng Y, Luo R, Wang K, et al. Kidney Disease is Associated with In-Hospital Death of Patients with COVID-19. *Kidney Int* 2020; 97: 829–838.

29. Poggiali E, Zaino D, Immonvilli P, et al. Lactate Dehydrogenase and C-Reactive Protein as Predictors of Respiratory Failure in CoVid-19 Patients. *Clin Chim Acta* 2020; 509: 135–138.

30. Kermali M, Khalsa RK, Pillai K, et al. The Role of Biomarkers in Diagnosis of COVID-19 - A Systematic Review. *Life Sci* 2020; 254: 117788.

31. Han Y, Zhang H, Mu S, et al. Lactate Dehydrogenase, a Risk Factor of Severe COVID-19 Patients: A Retrospective and Observational Study. *medRxiv* 2020; 2020.03.24.20040162.

32. Ferrari D, Motta A, Strollo M, et al. Routine Blood Tests as a Potential Diagnostic Tool for COVID-19. *Clin Chem Lab Med* 2020; 58: 1095–1099.

33. Frontera JA, Valdes E, Huang J, et al. Prevalence and Impact of Hyponatremia in Patients with Coronavirus Disease 2019 in New York City. *Crit Care Med* 2020; 48: e1211–e1217.

34. Tezcan ME, Dogan Gokce G, Sen N, et al. Baseline Electrolyte Abnormalities would be Related to Poor Prognosis in Hospitalized Coronavirus Disease 2019 Patients. *New Microbes New Infect* 2020; 37: 100753.

35. Yang X, Yu Y, Xu J, et al. Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. *Lancet Respir Med* 2020; 8: 475–481.